Metabolic
AOD-9604
AOD-9604 (hGH fragment 176-191)
AOD-9604 corresponds to residues 176-191 of the somatotropin sequence, the C-terminal region studied in early work for activity on adipose tissue in vitro. The research premise is separation of function: retaining lipolytic activity in assays while excluding the IGF-1-mediated signaling of the full-length molecule. Reported results across models have been more modest than preclinical rodent data suggested — a gap worth knowing before designing around it.
Research applications
- Lipolysis and β-adrenergic pathway assays in adipocyte culture
- Comparative studies against full-length hGH
- IGF-1 independence verification studies
Storage
Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days.
Reconstitution
Reconstitute with bacteriostatic water down the vial wall. Swirl gently.
Published literature
18 papers indexed on PubMed for AOD-9604. Showing 6, reviews first.
- 01Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF et al. · J Am Acad Orthop Surg Glob Res Rev · 2026
- 02Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM · Sports Med · 2026
- 03Human sports drug testing by mass spectrometry
Schänzer W, Thevis M · Mass Spectrom Rev · 2017
- 04Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls
Thevis M, Schänzer W · J Pharm Biomed Anal · 2014
- 05Obesity drugs in clinical development
Halford JC · Curr Opin Investig Drugs · 2006
ReviewPMID 16625817
- 06
Indexed from PubMed, 2026-07-19. We link to sources rather than reproducing them.
Related compounds
Semaglutide
5–20mg · COA published
Long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models.
- CAS
- 910463-68-2
- MW
- 4113.58
- Purity
- Per published certificate
Tirzepatide
10–30mg · COA published
Dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity.
- CAS
- 2023788-19-2
- MW
- 4813.45
- Purity
- Per published certificate
Retatrutide
10–30mg · COA published
Triple agonist at GIP, GLP-1, and glucagon receptors — among the most actively studied compounds in current metabolic research.
- CAS
- 2381089-83-2
- MW
- 4731.32
- Purity
- Per published certificate
Cagrilintide
10mg · COA published
Long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism.
- CAS
- 1415456-99-3
- MW
- 4409
- Purity
- Per published certificate
How AOD-9604 compares
Side-by-side against the compounds researchers most often weigh it against, with price per milligram, mechanism and the published certificate for each.
AOD-9604
From $44